Literature DB >> 18407551

SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population.

Karolien Bettens1, Nathalie Brouwers, Sebastiaan Engelborghs, Peter P De Deyn, Christine Van Broeckhoven, Kristel Sleegers.   

Abstract

SORL1 has recently been identified as a major genetic contributor to increased risk for late-onset Alzheimer disease (AD). Here we aimed at replicating this finding in a large, well-characterized group of 550 Belgian late-onset AD patients and 637 healthy control individuals using a gene-wide genotyping approach across the SORL1 locus. We observed significant associations, both for individual SNPs (SNPs 6, 8, 9, 10 and 27; p-values ranging from 0.001 to 0.040) and 3-SNP haplotypes (SNPs 5-6-7 and SNPs 25-26-27; p-values ranging from 0.008 to 0.035). Moreover, the associations at SNP 8, 9 and 10 represented a direct replication of the initial association data. Two signals in distinct regions of the gene were shown to be mutually independent, supporting allelic heterogeneity at the SORL1 locus in the Belgian population. Our findings confirm that genetic variants in SORL1 may be important risk factors for late-onset AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407551     DOI: 10.1002/humu.20725

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  50 in total

1.  SorLA in glia: shared subcellular distribution patterns with caveolin-1.

Authors:  Iris K Salgado; Melissa Serrano; José O García; Namyr A Martínez; Héctor M Maldonado; Carlos A Báez-Pagán; José A Lasalde-Dominicci; Walter I Silva
Journal:  Cell Mol Neurobiol       Date:  2011-11-30       Impact factor: 5.046

Review 2.  Mild cognitive impairment: pathology and mechanisms.

Authors:  Elliott J Mufson; Lester Binder; Scott E Counts; Steven T DeKosky; Leyla de Toledo-Morrell; Stephen D Ginsberg; Milos D Ikonomovic; Sylvia E Perez; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-11-19       Impact factor: 17.088

Review 3.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease.

Authors:  Liang-Hao Guo; Christine Westerteicher; Xin-Hui Wang; Martina Kratzer; Amalia Tsolakidou; Meizi Jiang; Timo Grimmer; Simon M Laws; Panagiotis Alexopoulos; Hideaki Bujo; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09       Impact factor: 5.270

5.  The Alzheimer's associated 5' region of the SORL1 gene cis regulates SORL1 transcripts expression.

Authors:  Jeanette J McCarthy; Sunita Saith; Colton Linnertz; James R Burke; Christine M Hulette; Kathleen A Welsh-Bohmer; Ornit Chiba-Falek
Journal:  Neurobiol Aging       Date:  2010-12-23       Impact factor: 4.673

6.  No association of psychosis in Alzheimer disease with neurodegenerative pathway genes.

Authors:  Mary Ann A DeMichele-Sweet; Lambertus Klei; Bernie Devlin; Robert E Ferrell; Elise A Weamer; James E Emanuel; Oscar L Lopez; Robert A Sweet
Journal:  Neurobiol Aging       Date:  2010-11-18       Impact factor: 4.673

Review 7.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

Review 8.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

Review 9.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Possible association between SORL1 and Alzheimer disease? Reanalysing the data of Shibata et al.

Authors:  Joseph H Lee; Nobuto Shibata; Rong Cheng; Richard Mayeux
Journal:  Dement Geriatr Cogn Disord       Date:  2008-11-04       Impact factor: 2.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.